Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders-Reference-Cited by-同舟云学术

Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders

Published:2017-09-22 Issue:1 Volume:5 Page:
ISSN:2050-7771
Container-title:Biomarker Research
language:en
Short-container-title:Biomark Res

Author:

Araki Wataru^ORCID,Hattori Kotaro,Kanemaru Kazutomi,Yokoi Yuma,Omachi Yoshie,Takano Harumasa,Sakata Masuhiro,Yoshida Sumiko,Tsukamoto Tadashi,Murata Miho,Saito Yuko,Kunugi Hiroshi,Goto Yu-ichi,Nagaoka Utako,Nagao Masahiro,Komori Takashi,Arima Kunimasa,Ishii Kenji,Murayama Shigeo,Matsuda Hiroshi,Tachimori Hisateru,Araki Yumiko M.,Mizusawa Hidehiro

Funder

National Center of Neurology and Psychiatry

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40364-017-0108-5.pdf

Reference41 articles.

1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5–36.

2. Sperling RA, Aisen PS, Beckett LA, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.

3. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's Disease: clinical trials and drug development. Lancet Neurol. 2010;9:702–16.